more
Joining forces to develop individualized antisense oligonucleotides for patients with brain or eye diseases: the example of the Dutch Center for RNA Therapeutics
Personal take on this article: This paper discusses the work of the Dutch Center for RNA Therapeutics (DCRT) in developing individualized antisense oligonucleotides (ASOs) for patients with rare brain or eye diseases. ASOs are short pieces of modified DNA that can adjust gene expression and have the potential to treat genetic disorders. However, many rare diseases are specific to individual patients, meaning pharmaceutical companies often overlook these cases due to …